Spreadsheet Data
Audit the saved peer set and the method inputs behind the blended fair value.
Review the saved peer set across price, scale, operating metrics, and raw valuation multiples.
| Peer | Price | Market Cap |
|---|
| Enterprise Value |
|---|
| Revenue |
|---|
| EBITDA |
|---|
| Net Income |
|---|
| P/E |
|---|
| P/S |
|---|
| EV/EBITDA |
|---|
ID IDYA IDEAYA Biosciences, Inc. FY ended Feb 13, 2026 | $40.11 | $3.87B | $3.30B | $218.71M | -$113.67M | -$113.70M | -31.34x | 17.70x | — |
EX EXEL EXELIXIS, INC. FY ended Feb 02, 2026 | $54.45 | $13.49B | $12.83B | $2.32B | $975.59M | $782.57M | 19.59x | 5.82x | 12.88x |
GI GILD GILEAD SCIENCES, INC. FY ended Feb 13, 2026 | $145.68 | $180.64B | $201.18B | $29.44B | $13.51B | $8.51B | 21.49x | 6.14x | 13.83x |
AM AMGN AMGEN INC FY ended Feb 10, 2026 | $432.42 | $233.78B | $260.45B | $36.75B | $14.04B | $7.71B | 30.39x | 6.36x | 18.55x |
AB ABBV AbbVie Inc. FY ended Feb 10, 2026 | $255.48 | $451.46B | $508.66B | $61.16B | $17.62B | $4.23B | 108.25x | 7.38x | 24.66x |
BM BMY BRISTOL MYERS SQUIBB CO FY ended Feb 04, 2026 | $66.58 | $136.00B | $156.99B | $48.19B | $14.61B | $7.05B | 19.24x | 2.82x | 9.39x |
See which peer averages feed the weighted fair value and which methods are excluded.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 14.51x | 5/6 | $71.70M | $0.33 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 7.70x | 6/6 | $586.88M | $2.69 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 27.94x | 6/6 | -$485.21M | — | Target fundamentals do not produce a usable positive equity value. |
Open the saved peer table used to audit the fair value view.
| Peer | Price | Market Cap | Enterprise Value | Revenue | EBITDA | Net Income | P/E | P/S | EV/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
ID IDYA IDEAYA Biosciences, Inc. FY ended Feb 13, 2026 | $40.11 | $3.87B | $3.30B | $218.71M | -$113.67M | -$113.70M | -31.34x | 17.70x | — |
EX EXEL EXELIXIS, INC. FY ended Feb 02, 2026 | $54.45 | $13.49B | $12.83B | $2.32B | $975.59M | $782.57M | 19.59x | 5.82x | 12.88x |
GI GILD GILEAD SCIENCES, INC. FY ended Feb 13, 2026 | $145.68 | $180.64B | $201.18B | $29.44B | $13.51B | $8.51B | 21.49x | 6.14x | 13.83x |
AM AMGN AMGEN INC FY ended Feb 10, 2026 | $432.42 | $233.78B | $260.45B | $36.75B | $14.04B | $7.71B | 30.39x | 6.36x | 18.55x |
AB ABBV AbbVie Inc. FY ended Feb 10, 2026 | $255.48 | $451.46B | $508.66B | $61.16B | $17.62B | $4.23B | 108.25x | 7.38x | 24.66x |
BM BMY BRISTOL MYERS SQUIBB CO FY ended Feb 04, 2026 | $66.58 | $136.00B | $156.99B | $48.19B | $14.61B | $7.05B | 19.24x | 2.82x | 9.39x |
Open the peer-average inputs behind the weighted result.
| Method | Type | Avg. Multiple | Coverage | Implied Equity Value | Fair Value / Share | Status |
|---|---|---|---|---|---|---|
EV / EBITDA EVActive | Enterprise Multiple | 14.51x | 5/6 | $71.70M | $0.33 | Included in the active peer mix. |
Price / Sales PSActive | Equity Multiple | 7.70x | 6/6 | $586.88M | $2.69 | Included in the active peer mix. |
Price / Earnings PEExcluded | Equity Multiple | 27.94x | 6/6 | -$485.21M | — | Target fundamentals do not produce a usable positive equity value. |
